NASDAQ:KRRO Korro Bio Q2 2026 Earnings Report $9.56 -0.01 (-0.06%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Korro Bio EPS ResultsActual EPS-$1.07Consensus EPS -$1.34Beat/MissBeat by +$0.27One Year Ago EPSN/AKorro Bio Revenue ResultsActual RevenueN/AExpected Revenue$0.21 millionBeat/MissN/AYoY Revenue GrowthN/AKorro Bio Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETUpcoming EarningsKorro Bio's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Korro Bio Earnings HeadlinesKorro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 21, 2026 | americanbankingnews.comKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 11, 2026 | markets.businessinsider.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 25 at 1:00 AM | Banyan Hill Publishing (Ad)Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 11, 2026 | globenewswire.comKorro to Participate in Upcoming Investor ConferencesAugust 27, 2026 | globenewswire.comKorro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA EditingAugust 20, 2026 | tipranks.comSee More Korro Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Korro Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Korro Bio and other key companies, straight to your email. Email Address About Korro BioKorro Bio (NASDAQ:KRRO) is a clinical-stage biotechnology company focused on developing RNA-editing medicines for genetic diseases. The company’s approach is designed to make precise changes to messenger RNA (mRNA), potentially correcting disease-causing genetic mutations without permanently altering a patient’s DNA. Korro’s technology platform uses short, chemically modified oligonucleotides to guide naturally occurring RNA-editing enzymes, including adenosine deaminase acting on RNA (ADAR), to targeted RNA sequences. By directing this editing activity, the company aims to restore or modify the production of disease-related proteins. The company’s development programs have included therapies for conditions such as alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene. Korro Bio is headquartered in Cambridge, Massachusetts, and is advancing its research through preclinical and clinical development programs. Its shares trade on the Nasdaq under the symbol KRRO.View Korro Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Super Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura DealCintas Raises Guidance as a Major Catalyst Moves Closer3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure Builds Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
